Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study on the Combination of Trabectedin and Olaparib in Unresectable Advanced/Metastatic Sarcomas After Failure of Standard Therapies

NCT02398058 is registered in ClinicalTrials.gov with Italian Sarcoma Group as lead sponsor.

NCT NCT02398058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02398058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study on the Combination of Trabectedin and Olaparib in Unresectable Advanced/Metastatic Sarcomas After Failure of Standard Therapies
Lead sponsor
Italian Sarcoma Group
Phase
Phase 1
Overall status
Completed
Start date
July 20, 2014
Completion date
December 1, 2019
Enrollment
50 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

bone tumor, soft tissue sarcoma